Transense Technologies had a strong end to it financial year.
In the year to June 2019, the temperature and torque monitoring technology developer generated revenues of around £2.22m, which was more than 10% ahead of expectations and up from £2.05m the previous year. This and control of overheads helped to reduce the loss.
Net cash was £2.6m at the end of June 2019. There should be a limited outflow this year and net cash could still be above £2m next year.
Subscription income from iTrack II services increased by 61% to £980,000. Translogik probe sales fell, but there are opportunities to gain orders via GE.
Revenues of £4m are forecast for this year, which would halve the loss to £900,000. Growing subscription revenues improve the quality and repeatability of revenues.
© 2019 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Omega Diagnostics will lose money this year, but it is on course to become profitable in 2020-21 as sales of the VISITECT CD4 test.
House broker Shore Capital has slashed its pre-tax profit forecast for engineer Tricorn Group by two-thirds to £420,000.
Evgen Pharma has entered into an agreement with The University of Dundee for the use of SFX-01 in a clinical trial in non-alcoholic steatohepatitis and liver fibrosis, where there is no existing treatment.